New PET tracer may reveal which bile duct cancers resist standard therapy
NCT ID NCT07673341
First seen Jun 29, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This trial investigates whether a special PET imaging tracer called [18F]FTT can help predict how well people with newly diagnosed bile duct cancer (cholangiocarcinoma) will respond to standard chemotherapy. The tracer binds to a protein called PARP1, which some tumor cells produce in high amounts. Researchers hope that by measuring PARP1 levels with a PET/CT scan, they can identify patients whose tumors may not respond well to treatment, potentially guiding future care decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fluorine F 18 Fluorthanatrace ([18F]FTT)
- What this could lead to
- If successful, this imaging method could help doctors identify which patients are unlikely to respond to standard chemotherapy, allowing for more personalized treatment plans.
- What could go wrong
- This is a small, early-phase trial, so the tracer may not reliably predict response. The results may not apply to all patients with cholangiocarcinoma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Web tool aims to empower rare cancer patients in genomic choices